Viritis Ltd was founded in 2022 with a mission to redefine how viral diseases are treated. We are developing a next-generation antiviral platform designed to rapidly generate targeted therapies against both existing and emerging viral threats. Our approach addresses a major gap in the pharmaceutical industry: the lack of scalable solutions for developing effective antivirals quickly and reliably.
Our founding team brings a unique combination of scientific, entrepreneurial, and financial expertise:
Dr. Amit Philosoph, Ph.D. in Molecular Genetics and Bioinformatics – with deep expertise in cellular mechanisms, clinical research, genetic engineering, and quality assurance. Amit Turman – a seasoned entrepreneur, mentor, and innovation program manager with a strong track record in guiding startups from concept to execution. Aaron Wistouch – a specialist in venture creation and financial institutions, ensuring the company is positioned for growth and partnerships.
Our vision and potential have already been recognized: Viritis was selected to join the NVIDIA Inception Program for cutting-edge startups and secured a grant from the Israeli Innovation Authority.
By combining breakthrough science with proven execution, Viritis is positioning itself as a leader in the next era of antiviral therapeutics.
our Mission
Viruses touch all of our lives.
Every day, billions of people—our families, friends, and communities—are exposed to common infections like measles, influenza, CMV, and herpes, as well as more dangerous threats such as Ebola, SARS, and West Nile virus.
Even with modern diagnostics and vaccines, there is still no reliable, scalable way to develop antiviral treatments when we need them most.
That’s why we created Viritis.
We all know the frustration of going to the doctor, only to hear the words “it’s viral, there’s nothing we can do.” Viritis is here to change that reality—developing antiviral treatments that give patients real options, so the world is no longer left unprepared against everyday infections or future viral threats.
our Innovative solution- EXHAUVIR
Viruses hijack our cells. We take them back! To replicate, viruses must take control of cellular mechanisms — causing widespread damage that can even progress to cancer. At Viritis, we’re not just reversing that process, we prevent it from happening at all.
Our platform combines our patented molecule, EXHAUVIR, with uniquely designed AI-driven tools to create highly specific antiviral drugs. These drugs penetrate infected cells, selectively destroy the virus, and crucially—leave healthy tissue and the host unharmed.
Unlike conventional treatments, EXHAUVIR is effective across all strains of the same virus and remains resilient to viral mutations. Its modular design enables us to rapidly adapt to any new viral threat, giving us a decisive advantage in both speed and precision.
By integrating synthetic biology, AI, molecular targeting, and rapid preclinical screening, we are redefining how the world develops antiviral treatments—building a future where humanity stays ahead of the viral arms race.
Why Now
The greatest challenge with viruses is their ability to rapidly mutate—making vaccines and existing drugs less effective, and often completely ineffective. Humanity is locked in a constant “arms race” with viruses, and today there is no scalable method to develop antiviral treatments quickly enough to stay ahead.
At Viritis, we’re changing that. Our platform is designed to be both fast and adaptable—enabling the rapid creation of targeted therapies against any viral threat, whether it’s a known infection like measles or emerging outbreaks such as chikungunya. With Viritis, the world no longer has to remain one step behind.
Looking Ahead
We are committed to create a robust pipeline of next-generation antivirals and other therapies, focusing on diseases where current options are limited or ineffective. As we advance through preclinical development, our strategy is clear: expand our technological capabilities, forge strategic partnerships, and accelerate our path toward clinical validation.
Viritis is more than a drug developer — we are creating a new engine for rapid therapeutic innovation, designed to keep humanity ahead of viral threats.